Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08YWY
|
||||
| Former ID |
DNCL001681
|
||||
| Drug Name |
SCH-900117
|
||||
| Indication | Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] | Phase 1 | [1] | ||
| Company |
Merck
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-17 | Target Info | Modulator | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Inflammatory bowel disease (IBD) | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Pathway Interaction Database | IL27-mediated signaling events | ||||
| IL23-mediated signaling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| Allograft Rejection | |||||
| IL17 signaling pathway | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029914) | ||||
| REF 2 | Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76. doi: 10.1038/nrd3794. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.